In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

Here's why brokers are feeling bullish about these three shares this week. The post Brokers name 3 ASX shares to buy today ...

The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. OUT, ...

Three Australian fund managers who delivered annualised double-digit returns over the past 10 years share their views on what ...

The fourth-quarter 2024 earnings season will kick off this week, with banking sector players due to report numbers. The ...

If you have a full-face mask, plan to replace this cushion once per month ... The newer DreamStation has two integrated filters that can be replaced with this same frequency. The ResMed AirSense ...

Magnets in continuous positive airway pressure (CPAP) masks led to Class I recalls in recent years for Philips Respironics and ResMed. Brushless DC motors are a promising alternative to traditionally ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...